Access Restriction

Author El-Aal, Hisham H. Abd ♦ Emmad, M. D. ♦ Habib, E. ♦ Mishrif, Mohamed M.
Source CiteSeerX
Content type Text
File Format PDF
Subject Domain (in DDC) Computer science, information & general works ♦ Data processing & computer science
Subject Keyword Kasr El-aini Center ♦ Radiation Oncology ♦ Nuclear Medicine ♦ Pediatric Unit ♦ M2 I.v Day ♦ Kg Day Day ♦ Fifty-five New Case ♦ M2 I.v ♦ Para-testicular Embryonal Rhabdomyo-sarcomas ♦ Pediatric Unit Outpatient Clinic ♦ Pediatric Rhabdomy-osarcoma ♦ Median Follow-up ♦ High-risk Patient ♦ Safety Margin ♦ Overall Survival ♦ Cisplatinum I.v ♦ Pediatric Unit Clinic ♦ Retrospective Analysis ♦ Conventional Fractionation Radiotherapy ♦ Treatment Result ♦ Chemo-therapy Regimen ♦ Nuclear Med-icine ♦ Low-risk Patient ♦ Treatment Response ♦ Stage Iii ♦ Present Study ♦ New Rhabdomyosarcoma Pediatric Patient ♦ Pediatric Unit Out-patient Clinic ♦ Ii Orbital ♦ Radiation Volume ♦ Pedi-atric Rhabdomyosarcoma ♦ Palliative Radiation Therapy ♦ Disease Free Survival ♦ Conventional Fractionation Radiation Therapy
Abstract Our present study is a retrospective analysis of the treatment results of new rhabdomyosarcoma pediatric patients who had attended the pediatric unit clinic of Kasr El-Aini Center of Radiation Oncology and Nuclear Med-icine (NEMROCK) from January 1992 to January 2001). Patients and Methods: Fifty-five new cases of pedi-atric rhabdomyosarcoma attended the pediatric unit out-patient clinic of (NEMROCK) from the period of January 1992 until January 2001. Patients were divided into 4 stages and classified into low-risk patients and high-risk patients according to the extent of resection. Stage I, II orbital and stage I para-testicular embryonal rhabdomyo-sarcomas received 32 weeks of vincristine and actinomy-cin-D (vincristine 1.5mg/m2 weekly, actinomycin-D 0.015mg / Kg/day day 1 to day 5). Other pathologies, sites and stages received 52 weeks of chemotherapy. Chemo-therapy regimens included VAC (vincristine 1.5mg/m2 weekly, actinomycin-D 0.015mg/Kg/day day 1 to day 5 and endoxan 2.2gm/m2 I.V with mesna every 21 days), VAI (vincristine, actinomycin-D and ifosfamide 1.8gm/m2 I.V day 1 to day 5 with mesna) or VIE (vincristine, ifosfamide and vepesid 100mg/m2 I.V day 1 to day 5) [11,12]. Stages I and II received conventional fractionation radiotherapy 4140cGy on week 13, stages III and IV received conventional fractionation radiation therapy 5040cGy also, on week 13. The radiation volume included the tumor bed with a 2cm safety margin at least. Relapsing cases received palliative radiation therapy and chemother-apy (cisplatinum I.V 100mg/m2 divided over 2 days and vepesid 100mg/m2 I.V day 1 to day 3 to be recycled every 21 days). Patients were followed-up for 5 years, with a median follow-up of 36 months. Overall survival, disease free survival, treatment response, and complications of treatment were assessed and statistically analyzed. Results: Fifty-five new cases of pediatric rhabdomy-osarcoma attended the pediatric unit outpatient clinic of (NEMROCK) and were evaluated. Males constituted about
Educational Role Student ♦ Teacher
Age Range above 22 year
Educational Use Research
Education Level UG and PG ♦ Career/Technical Study
Publisher Date 1992-01-01